The phase II study of pembrolizumab plus lenvatinib for patients with unresectable cutaneous angiosarcoma (Pembro-Lenva for cAS/PLAS trial).

Authors: Dai Ogata, Eiji Nakano, Takeru Funakoshi, Akira Takahashi, Jun Asai, Motoki Nakamura, Kenjiro Namikawa, Ryunosuke Machida, Masayuki Yokoyama, Haruhiko Fukuda, Yukari Nagasaka, Kazumi Kurishita, Yoshie Shuda, Kenta Anjo, Kanako Kondo, Masako Inaba, Satoshi Kawashima, Takako Hitomi, Natsuko Tsuda Okita, Naoya Yamazaki

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps11586

Source: Full article

---

Abstract

TPS11586